Anticancer activities of genistein-topotecan combination in prostate cancer cells

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 11, 2012, Pages 2631-2636

  Hörmann, Vanessa ^a   Kumi Diaka, James ^a   Durity, Marcia ^b   Rathinavelu, Appu ^b  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Genistein; Prostate cancer; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; GENISTEIN; REACTIVE OXYGEN METABOLITE; TOPOTECAN;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CULTURE MEDIUM; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA; DNA FRAGMENTATION; ENZYME ACTIVATION; GENISTEIN; HUMANS; MALE; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; TOPOTECAN;

EID: 84868101749     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01576.x     Document Type: Article

References (33)

1. American Cancer Society. Prostate Cancer Detailed Guide [Internet] [accessed October 12, 2011; cited November 1, 2011]. Available from: http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-key-statistics.
2. Fukutake M, Takahashi K, Ishida H, et al. Quantification of genistein and genistein in soybeans and soybean products. Food Chem Toxicol. 1996; 34: 457-61.
3. Lamartiniere CA. Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr. 2000; 71: 1705S-7S.
4. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1993; 85: 1819-27.
5. Kumi-Diaka JK, Hassanhi M, Merchant K, Hormann V. Influence of genistein isoflavone on matrix metalloproteinase-2 expression in prostate cancer cells. J Med Food. 2006; 9: 491-7.
6. Kumi-Diaka JK, Merchant K, Haces A, et al. Genistein-selenium combination induces growth arrest in prostate cancer cells. J Med Food. 2009; 13: 842-50.
7. Kumi-Diaka J, Saddler-Shawnette S, Aller A, Brown J. Potential mechanism of phytochemical-induced apoptosis in human prostate adenocarcinoma cells: therapeutic synergy in genistein and beta-lapachone combination treatment. Cancer Cell Int. 2004; 4: 5.
8. Balabhadrapathruni S, Thomas TJ, Yurkow EJ, et al. Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDA-MB-468 human breast cancer cells. Oncol Rep. 2000; 7: 3-12.
9. Seo HS, Ju J, Jang K, Shin I. Induction of apoptotic cell death by phytoestrogens by up-regulating the levels of phospho-p53 and p21 in normal and malignant estrogen receptor α-negative breast cells. Nutr Res. 2011; 31: 139-46.
10. Zhou N, Yan Y, Li W, et al. Genistein inhibition of topoisomerase IIalpha expression participated by Sp1 and Sp3 in HeLa cell. Int J Mol Sci. 2009; 10: 3255-68.
11. Li Z, Li J, Mo B, et al. Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. Cell Biol Toxicol. 2008; 24: 401-9.
12. Law C. Basic research plays a key role in new patient treatments. J Natl Cancer Inst. 1996; 88: 869.
13. McNeil C. Topotecan: after FDA and ASCO, what's next? J Natl Cancer Inst. 1996; 88: 188-9.
14. Ulukan H, Swaan PW. Camptothecins: a review of their chemotherapeutic potential. Drugs. 2002; 62: 2039-57.
15. Wall ME, Wani MC, Cook CE, et al. Plant antitumour agents I, the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from camptotheca acuminate. J Am Chem Soc. 1966; 88: 3888-90.
16. Padzur R. FDA approval for topotecan hydrochloride [Internet]. National Cancer Institute [accessed January 14, 2011; cited November 1, 2011]. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-topotecan-hydrochloride.
17. Redinbo MR, Stewart L, Kuhn P, et al. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 1998; 279: 1504-13.
18. Adams DJ, Wahl ML, Flowers JL, et al. Camptothecin analogs with enhanced activity against human breast cancer cells II Impact of the tumour pH gradient. Cancer Chemother Pharmacol. 2006; 75: 145-54.
19. Ohneseit PA, Prager D, Kehlbach R, Rodeman HP. Cell cycle effects of topotecan alone and in combination with irradiation. Radiother Oncol. 2005; 75: 237-45.
20. Timur M, Akbas SH, Ozben T. The effect of Topotecan on oxidative stress in MCF-7 human breast cancer cell line. Acta Biochim Pol. 2005; 52: 897-902.
21. Erlichman C, Boerner SA, Halgren CG, et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 2001; 61: 739-48.
22. Bruzzese F, Rocco M, Castelli S, et al. Synergistic antitumour effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther. 2009; 8: 3075-87.
23. Jeune MA, Kumi-Diaka J, Bown J. Anticancer activities of pomegranate extracts and genistein in human breast cancer cells. J Med Food. 2005; 8: 469-75.
24. Merritt WM, Danes GC, Shahzad MM, et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009; 8: 1596-603.
25. Tomicic MT, Christmann M, Kaina B. Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. J Pharmacol Exp Ther. 2010; 332: 316-25.
26. McCubrey JA, Chappell WH, Abrams SL, et al. Targeting the cancer initiating cell: the Achilles' heel of cancer. Adv Enzyme Regul. 2010; 51: 152-62.
27. Aguero MF, Venero M, Brown DM, et al. Phenoxodiol inhibits growth of metastatic prostate cancer cells. Prostate. 2010; 70: 1211-21.
28. Hsu A, Bray TM, Helferich WG, et al. Differential effects of whole soy extract and soy isoflavones on apoptosis in prostate cancer cells. Exp Biol Med. 2010; 235: 90-7.
29. Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem. 2004; 91: 491-503.
30. Kumar R, Verma V, Jain A, et al. Synergistic chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer. J Nutr Biochem. 2011; 8: 723-31.
31. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008; 7: 1001-12.
32. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005; 55: 178-94.
33. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006; 25: 4798-811.